INTRODUCTION
The 2-oxo acid dehydrogenase complexes represent the classic examples of multienzyme complexes, a knowledge of whose structure and function has wide implications for our understanding of macromolecular assembly and organization and of protein structure and function. Each complex consists of multiple copies of three enzymes, termed El, E2 and E3. El is a 2-oxo acid dehydrogenase which has thiamin pyrophosphate as an essential co-factor. E2 is a dihydrolipoamide acyltransferase, with a covalently attached lipoic acid cofactor, and E3 is an FAD-containing dihydrolipoamide dehydrogenase. The components catalyse consecutive steps in the overall reaction, as outlined in Fig. 1 . These complexes have molecular masses of several million [mammalian pyruvate dehydrogenase complex (PDC) is slightly larger than a ribosome] and are truly self-assembling [1, 2] .
These macromolecules are not however merely of interest from a structural viewpoint. Each of the 2-oxo acid dehydrogenase complexes occupies key positions in intermediary metabolism and the activity of each mammalian complex, located within mitochondria, is under stringent control by hormones and dietary factors. PDC oxidatively decarboxylates pyruvate to acetyl-CoA, an irreversible step in the utilization of carbohydrate, whilst 2-oxoglutarate dehydrogenase complex (OGDC) is a potentially regulatory enzyme of the tricarboxylic acid cycle. Branched-chain 2-oxo acid dehydrogenase complex (BCOADC) catalyses an irreversible step in the catabolism of several essential amino acids, including the branched-chain amino acids [2] . PDC and OGDC have narrow substrate specificities, with OGDC being essentially specific for 2-oxoglutarate, whereas PDC will oxidize 2-oxobutyrate, in addition to pyruvate, at a significant rate [3] . In contrast, BCOADC has a relatively broad specificity, oxidizing 4-methylthio-2-oxobutyrate and 2-oxobutyrate at comparable rates and with similar Km values as for the three branched-chain 2-oxo acid substrates, namely 3-methyl-2-oxobutyrate, 4-methyl-2-oxopentanoate and 3-methyl-2-oxopentanoate [3] [4] [5] . BCOADC will also oxidize pyruvate, but the Km value is approx. 1 mm (as compared with 30 /uM with PDC [4] ), making this unlikely to be ofphysiological significance [5] .
Structural analysis of the complexes
The powerful combination of protein chemistry and molecular genetics has led to elucidation of the structure and function of the complexes. Much of the structural analysis has been carried out using complexes of bacterial origin, although recently significant progress has been made with the mammalian complexes.
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The E2 component of the respective complexes is the key to their structure and function. It serves three major roles: (1) . it forms a central, symmetrical core around which are arranged multiple copies of the El and E3 components, (2) it is an acyltransferase, catalysing the formation of the acyl-CoA product, and (3) it provides the attachment site for the lipoic acid cofactor which interacts with the different active sites in the complexes. It has been shown recently by 1H-n.m.r. that acetylation occurs at the 8-S position of the lipoic acid and not at the 6-S position, although isomerization can occur in aqueous solution [6] .
The E2 components of the complexes are arranged with point group symmetry. OGDC and BCOADC have 24 copies of E2 arranged with 432 (octahedral) symmetry as does PDC from Gram-negative bacteria, whilst PDC from mammals, birds, yeast and Gram-positive bacteria has 60 copies of E2 arranged with 532 (icosahedral) symmetry [7] .
Studies principally utilizing limited proteolysis have demonstrated that the E2 of the different complexes consists of several functional domains [8] [9] [10] [11] [12] [13] [14] . These include a compact, inner catalytic domain which, in addition to containing the active site, binds to other E2 catalytic domains to maintain the central core and also is responsible for binding of the El component of the complexes. The second type of domain is an extended, outer domain which contains the lysine group to which the lipoic acid cofactor is attached via a thioester linkage. The lipoate domains apparently interdigitate between the El and E3 components. Each E2 also contains a distinct region of polypeptide, thought to be present as a folded domain, which is responsible for binding of the E3 components [15] . The different domains are joined by linker regions of polypeptide, which vary in length and are characterized by being rich in proline, alanine and charged amino acid residues [16] . 'H-n.m.r. spectroscopy has shown that these linker regions are extremely flexible, giving highly characteristic sharp resonances [17, 18] , which are diminished in genetically engineered complexes lacking some of the linker regions [19] . Furthermore, additional resonances are detected when a histidine residue is introduced, again by site-directed mutagenesis, into one of the linker regions [20] .
The complexes vary in the number of lipoate domains which are contained within the E2 polypeptide. E2 from PDC of Escherichia coli is remarkable in that it contains three highly-conserved lipoate domains, located in tandem repeat at the N-terminus of the polypeptide [16] . Surprisingly, deletion of two of the three lipoate domains by site-specific mutagenesis still allows assembly of a functional complex with full catalytic activity [21] . Clearly the additional domains are not required for the catalytic functioning of the complex, which of course raises the interesting question of the function of the two additional lipoate domains.
Mammalian OGDC and BCOADC have a single lipoate domain and, although there is some evidence from isotope dilution studies that mammalian PDC also has a single lipoate residue [22] , there is recent evidence that the E2 polypeptide has two lipoate residues [23] . This is indicated by cross-linking studies using phenylene-O-bismaleimide, in the presence of 2-oxo acid substrate, to form cross-links between lipoate residues. Whereas the E2 of OGDC is able to form only dimers, consistent with the presence of a single lipoate, E2 of PDC is apparently capable of cross-linking to form dimers, trimers and higher aggregates, an observation best explained by the presence of two or more lipoate residues. Furthermore the predicted protein sequence of a partial cDNA clone of rat liver PDC E2 [24] is consistent with the possible presence of a second lipoate domain (see below). A schematic representation of the domain structure of the different E2 components is given in Fig. 2 .
The situation with mammalian PDC is further complicated by the presence of an additional component X which co-purifies with, and is tightly bound to, E2 [25, 26] . Previously it was generally assumed that protein X was merely a proteolytic fragment of E2 but there is now convincing immunological and protein chemical data indicating that X is a distinct polypeptide. Antibodies raised against E2 fail to recognize X and vice versa, and limited proteolytic digestion yields a different pattern of peptides derived from E2 and X [25] it has been shown that protein X contains at least one lipoate moiety which can be reductively acetylated [27] .
One possibility is that X is an isoenzymic form of E2 but the observation that E2 and X are present in approximately the same ratio in nine different rat tissues argues against X being a tissue-specific isoenzyme [23] . As the other complexes (apparently) do not possess a protein corresponding to X it seems unlikely that X is necessary for the catalytic functioning of mammalian PDC. Evidence has been presented that X is responsible for binding of the PDC kinase to the complex [28] and that the oxidative state of the lipoic acid residue in X serves a regulatory function by controlling the activity of the PDC kinase [29] , but this has yet to be firmly established.
Surprisingly little is known concerning the enzymes responsible for attachment and removal of the lipoic acid cofactor. Whilst it seems likely that the ligase responsible for attachment of the lipoate is located within mitochondria there is no direct evidence in support of this. The sequence surrounding the lipoate attachment site on several bacterial and mammalian complexes has now been determined [16, [30] [31] [32] [33] , as has the lipoate-containing H-protein ofthe glycine cleavage system [34] . The Molecular cloning of the bacterial and mammalian complexes A major development in the study of the complexes was the work of John Guest and co-workers who cloned and sequenced the genes encoding the components of PDC and OGDC of E. coli, namely the aceE (El, PDC) [35] , aceF (E2, PDC) [16] , sucA (El, OGDC) [36] , sucB (E2, OGDC) [30] and lpd (E3) genes [37] . Analysis of the predicted protein sequences of the El components of PDC and OGDC shows, perhaps surprisingly, very little similarity with each other, whereas the E2 components exhibit a high degree of similarity (for recent reviews see [7, 38] ). Furthermore, analysis of the amino acid sequences reveals similarity with several chloramphenicol acetyltransferases and has led to a proposed catalytic mechanism, involving a histidine residue in each E2 as a likely active site residue [39] .
Very recently, several papers have been published reporting the molecular cloning and sequence analysis of cDNAs encoding all or part of the constituent polypeptides of the components of the eukaryotic 2-oxo acid dehydrogenase complexes.
To date, three groups have reported the cloning and sequencing of a full-length cDNA encoding the ac-subunit of the El of human PDC. All three reported sequences are significantly different [40] [41] [42] ! However, several important consistent features are found in each reported sequence: (1) the mature polypeptide is produced after cleavage of a 29-residue leader sequence necessary for mitochondrial targetting, (2) the phosphorylation sites lie in the C-terminal half of the polypeptide, and (3) there is no significant similarity between the a-subunits and the single subunit of the El components of the bacterial PDC and OGDC. A cDNA encoding the cx-subunit of El of BCOADC from rat liver has also been cloned and sequenced [43] and analysis of the predicted protein sequence indicates a high degree of similarity with the a-subunit of PDC. Again, a leader sequence, this time of 40 amino acid residues, is present and again the phosphorylation sites lie in the C-terminal segment of the protein. Perhaps surprisingly there is as yet no sequence information available concerning the single subunit of El of the mammalian OGDC, and it will be interesting to see whether that polypeptide exhibits significant similarity to its prokaryotic counterpart.
Vol.-257 Molecular cloning and sequence analysis of cDNA molecules encoding all or part of the E2 components of mammalian PDC and BCOADC has also been reported recently [24, 33, 44] . The rat liver PDC E2 protein shows a high degree of similarity both with its counterpart from E. coli and with the E2 component from human and bovine BCOADC. The reported sequence for E2 of PDC apparently encodes most of the polypeptide but is lacking the majority of the N-terminal lipoate domain and a small section at the C-terminal end of the polypeptide, whereas the BCOADC clone is lacking the sequence corresponding to the majority of the catalytic domain. However, the BCOADC E2 clone indicates that an extended leader sequence of 56 residues is present [44] . Molecular cloning of full-length cDNAs for both human [45] and yeast [46] E3 polypeptide has also been reported. These sequences indicate that E3 is a highly conserved protein, with about 41 % overall identity in the protein sequence of yeast and E. coli and 44 % identity between human and E. coli, with even higher conservation of sequence around the cysteine residues of the active site. Rat liver mitochondria contain two forms of E3 which can be distinguished immunologically [47] and it has been suggested that the second form is specifically involved in the glycine cleavage system, a second enzyme system which utilizes lipoic acid as an essential cofactor [34] .
Biosynthesis and import of the eukaryotic complexes
All the subunits of the mitochondrial complexes are encoded by genes in the nucleus. The nascent polypeptides must therefore be imported into the mitochondrial matrix across two membranes, a process which is energy-dependent and which involves proteolytic cleavage of the polypeptides [48] . Furthermore, the appropriate cofactors must be inserted into the constituent polypeptides which must fold and aggregate into the mature correctly assembled complexes.
Current information indicates that all of the constituent polypeptides of the complexes (with the possible exception of component X of PDC) are cleaved near to their N-terminus during import, but the size of the cleaved fragment seems to vary considerably. As discussed above, comparison of the sequence predicted from cDNA sequences for -the a [40] [41] [42] and fi [41] subunits of PDC El and the El a-subunit of BCOADC [41] with N-terminal protein sequences of the mature polypeptides indicates that leader sequences of approx. 30 amino acids are removed during import. This is consistent with data from cultured cells which show that, in the presence of uncoupler to inhibit uptake and processing, precursors of the a and f, subunits of PDC El accumulate which have an apparent molecular masses approx. 3 kDa greater than those of the mature polypeptides [49] . Similarly, precursors corresponding to the individual subunits of OGDC accumulate in the cytoplasmic fraction when cells are maintained in the presence of uncouplers [50] . The apparent molecular masses of the precursor forms of E2 from PDC and OGDC are approx.
8 kDa greater than those of the mature E2s [49, 50] , but unfortunately the cleavage point has not yet been confirmed as no sequence information on the N-terminus of the mature E2 polypeptides has yet been obtained. However, these large differences in apparent size between the precursor and mature forms of the E2 components are consistent with the presence of a large signal peptide of 56 residues on the E2 of BCOADC [44] . Phosphorylation of eukaryotic PDC and BCOADC The activities of both mammalian PDC and BCOADC are subject to regulation by reversible phosphorylation [2, 51] . In each case the effect of phosphorylation is to cause inactivation of the complex by a dramatic reduction of the Vmax. It appears that the phosphorylated form is catalytically inactive as no allosteric activators of the phosphorylated complexes have been found. In both complexes phosphorylation occurs exclusively on the a-subunit of El. In PDC, three serine residues on the a-subunit undergo phosphorylation [52, 53] , whilst two sites on the a-subunit of BCOADC are subject to phosphorylation [54] [55] [56] . In each complex, phosphorylation of one site is primarily responsible for inactivation and the role of the additional sites has yet to be firmly established, although there is evidence that the additional sites on PDC may inhibit dephosphorylation of the inactivating site [57] .
As yet there is no convincing evidence for phosphorylation of PDC from yeast. However the El component of yeast PDC can be phosphorylated in vitro by bovine kidney PDC kinase and the site of phosphorylation is very similar in primary structure to the major inactivating site in the mammalian complex [58] , indicating that the yeast complex at least has the potential to be regulated by reversible phosphorylation.
Properties of the relevant protein kinases and phosphatases
The kinases and phosphatases acting on PDC and BCOADC are specific for each complex and appear distinct from any of the cytoplasmic kinases or phosphatases, with the exception of a recently discovered mitochondrial PDC phosphatase termed phosphatase SP [59] . However, as no primary structure-information is available for any of the regulatory enzymes, it may yet turn out that these mitochondrial enzymes are related to some of the well-characterized cytoplasmic protein kinases and phosphatases. The kinases are tightly bound to, and copurify with, their respective complexes, whereas the phosphatases are more loosely associated and are purified as distinct, soluble enzymes.
PDC kinase has been purified to homogeneity and its structure elucidated [60] . It consists of two non-identical subunits termed a. and fi, which have molecular masses of 48000 and 45000 respectively, and the kinase is apparently a dimer. Limited proteolytic studies have indicated that the a-subunit contains the kinase active site and it has been postulated that the f-subunit may serve a regulatory role [60] but there is no evidence in direct support of this. PDC kinase is specific for PDC and has little activity against other protein substrates, including BCOADC. The activity of the kinase is stimulated by acetyl-CoA and NADH, products of the complex, and this stimulation is antagonized by the substrates CoA and NADI. It is also inhibited by pyruvate and by thiamin pyrophosphate, which presumably binds directly to the active site of the El substrate (for a recent review, see [51] ).
The homogeneous preparations of PDC kinase in [60] were obtained from an E2-kinase subfraction of the complex. It has bee-n reported more recently that a significant proportion of the kinase remains associated (Jeremy et al., 1985a,b, 1986a ). Aortae were cleared of adventitia and cut into 1 mm rings with a scalpel blade on a Teflon block. Tissues were pooled and randomized in KRB and incubated at 37°C for 6 h in a shaking water bath to allow preparation-elicited prostanoid synthesis to subside (Jeremy et al., 1984 (Jeremy et al., , 1985a (Jeremy et al., , 1986a ) before incubation with chelators and agonists. In all experiments, polypropylene flasks and tubes were used to obviate glass-derived contamination of buffers w!ith iron and other tervalent cations. Incubation of aortic tissue with agonists and chelators After 6 h preincubation, four aortic rings were placed in 1 ml of KRB containing chelators of different concentrations (1 x i0--x 10-2 mol-l-'), in sextuplicate for each chelator concentration. Two untreated batches (without chelators) were included, one of which was the zero basal group and the other the agonist alone group. The tissues were equilibrated for 60 min at 37°C, the KRB aspirated and fresh KRB containing the same concentrations of chelators was added. Pr stanoid synthesis was then stimulated by the addition of adrenaline (3 x 1o-6 mol -l-l final concn.; Jeremy et al., In order to test whether the chelators were removing an obligatory metal cation or were exerting la direct action on prostanoid-synthesizing enzymes, tissties were preincubated for 4 h with the chelators, the buffer (containing the same concentrations of chelatots) being changed every 30 min. The tissues were then w4shed in chelator-free KRB made up in deionized double' distilled water, and prostanoid synthesis was stimulated with arachidonate, as described above.
In separate experiments the effects of FeCl3 as well as AlCl3 (up to 1 mmol l-1) on agonist-stimulated synthesis de novo of aortic PGI2 and interactions of iron and aluminium with chelators on PGI2 synthesis were also studied by the same method as that described above.
The effect of ascorbic acid and H202 on aortic PGI2 synthesis de novo was investigated singly in separate experiments as for the action of agonists on prostanoid synthesis (Jeremy et al., 1985a,b, 1986a) . The effect of H202 and ascorbic acid on chelator inhibition of aortic PGI2 synthesis was subsequently studied as described above.
Radioimmunoassay of 6-oxo-PGF1. 
RESULTS
Effect of chelators on adrenaline-, ionophore-A23187-and arachidonate-stimulated PGI2 synthesis Desferrioxamine, LI, LINEt and L1NPr inhibited adrenaline-, Ca2+-ionophore-and arachidonate-stimulated PGI2 synthesis by aortic tissue in concentrationdependent fashion (Figs. 1, 2 and 3) . The quantities of PGI2 released in response to agonists is given in the 1988 240 complex [4, [63] [64] [65] , it has been shown, using perfused hearts [85] and hepatocytes isolated from rats fed a lowprotein diet [86, 87] , that flux through the complex is increased by the presence of 2-oxo acid substrates in the incubation medium. This results from activation of the complex, observed as an increase in the activity of the complex in extracts prepared from perfused hearts or hepatocytes [65, 86] . Using specific antibodies to immunoprecipitate El from extracts prepared from cells preincubated with [32P]P1, decreased phosphorylation of the a-subunit of El at both phosphorylation sites in response to 2-oxo acids has been demonstrated directly in hepatocytes [83] . Similar experiments have also been carried out with isolated adipocytes [88] . The classical acute hormonal effect on the activity of the complexes is the dephosphorylation and activation of PDC in adipose tissue by insulin (reviewed in [51] ), mediated via stimulation of PDC phosphatase [89] by an unknown mechanism which does not involve increases in the intramitochondrial concentrations of free Ca2l ions [90] . The effects of insulin on the phosphatase persist during homogenization of the tissue, preparation of mitochondria and subsequent pe'rmeabilization of these mitochondria with toluene [91] . However these effects are lost in extracts prepared from these mitochondria [80, 90] . The effect of insulin is to lower the K. for Mg2" ions [80, 91] , an effect mimicked on purified phosphatase by the polyamine spermine [80, 92] . This has led to the suggestion that spermine or a spermine-like compound may mediate insulin's effect on the phosphorylation state of PDC [92] , but as the insulin effect persists in mitochondria, which are likely to be permeable to spermine, and exogenous spermine has no effect on the activity of PDC phosphatase in these permeable mitochondria, it has been suggested that a high-M, molecule, perhaps with some spermine-like properties, may mediate the intramitochondrial actions of insulin [91] . Long-term physiological regulation of PDC and BCOADC The activities of mammalian PDC and BCOADC are under long-term control and vary in response to diabetes and diet. During long-term starvation (48 h) or in alloxan-induced diabetes, the activity state of PDC in heart, liver and kidney drops significantly [93, 94] . This is primarily due to increased activity of PDC kinase, to which several mechanisms contribute. Increased lipid oxidation increases the ratios of acetyl-CoA/CoA and NADH/NAD+, causing acute activation of the kinase [95] , but there are also mechanisms for a stable increase in kinase activity [96] [97] [98] [99] . It appears that there is an increase of 2-3-fold in the amount of kinase activity associated with the complex, but also a 2-fold increase in the amount of a kinase activator protein which can be resolved from the complex by gel filtration chromatography [98] . However, the activator protein has not yet been purified and fully characterized, and it cannot be firmly excluded that the kinase activator is in fact additional kinase molecules which dissociate from, or are unable to bind to, the complex. Such a conclusion must await purification of the activator and investigation of whether it possesses PDC kinase (or PDC kinase kinase!) activity.
The primary site of oxidation of branched-chain amino and 2-oxo acids is the liver. Other tissues such as heart and skeletal muscle contain significant levels of BCOADC, but the enzyme is primarily in the phosphorylated, inactive form [100] [101] [102] [103] ,
In the liver of rats fed a standard chow diet with a protein content of approx. 20 % or greater, the complex is essentially all in the active form, with an activity state of 90 % or higher [101, 103, 104] . Feeding a diet with a restricted protein content leads to a reduction in the activity state [103] [104] [105] . The decrease occurs within 2-3 days and the final value obtained is related to the protein content of the diet [104] . Such a reduction in the activity of BCOADC in liver will allow conservation of the essential branched-chain amino acids during times of negative nitrogen balance. An explanation for the decreased activity state during times of restricted protein intake has been provided by the finding of a 4-fold increase in kinase activity under those conditions [106] . Clearly the mechanism responsible for these changes in kinase levels is an important outstanding question. There is also evidence that total activity of BCOADC is decreased in the livers of rats fed a diet low in protein [100, 103, 104] but this is contradicted by immunoassay studies utilizing antibodies raised against one or more of the components of -the complex. [105, 107] .
It now seems clear, from freeze-clamping studies, that during starvation the high activity state of BCOADC in liver is maintained, to allow utilization of branchedchain amino and 2-oxo acids as glucogenic and ketogenic precursors [103, 105] . Furthermore, starvation of rats previously fed a low-protein diet leads to re-activation of the complex in liver, although the complex in heart is apparently insensitive to starvation [103] . Earlier data indicating that starvation causes a dramatic decrease in the activity state in liver [107] can be at least partly explained by the findings that, despite precautionary measures, the activity state can alter dramatically during preparation of mitochondria from starved animals [108] . Maintenance of the high activity state of the complex in liver upon starvation of rats fed previously a highprotein diet is consistent with the finding that levels of kinase activity are unaffected by starvation [106] . Role of complexes in primary biliary cirrhosis Primary biliary cirrhosis is a cholestatic liver disease characterized by inflammatory obliteration of intrahepatic bile ducts, leading to liver cell damage and cirrhosis [109] . It is apparently an autoimmune process, characterized particularly by the presence of anti-mitochondrial antibodies in the sera of patients [110, 111] . A variety ofmitochondrial autoantigens have been reported [112,113J and their identities suggested but, until recently, no autoantigen had been conclusively identified. Two mitochondrial antigens of apparent Mr 70 000 and 45 000 on SDS/polyacrylamide-gel electrophoresis have been characterized [114] and using antisera from primary biliary cirrhosis patients to screen a rat liver cDNA library, the cDNA coding for the Mr 70000 antigen has been cloned "and the resultant cDNA sequenced, although surprisingly this did not lead to identification of the autoantigen [24] .
Detailed inspection of the protein sequence predicted from the cDNA allows identification of the autoantigen as the E2 component of'PDC [115] . In particular, the predicted protein sequence contains a region corresponding to the site of attachment of the lipoic acid cofactor [31] . The identification of the autoantigen has been substantiated using immunoblotting of patients' 2-Oxo acid dehydrogenase complexes sera against purified bovine E2, where it was found that approx. 95 % of primary biliary cirrhosis patients possess autoantibodies against E2. Interestingly, all sera from these patients also cross-react with protein X present in the preparations of E2 which were used [1 15 ], whilst sera from some patients recognize the E2 components of OGDC and BCOADC [116] . Whilst it is still unclear what role, if any, the presence of circulating antibodies plays in the pathogenesis of the disease, the availability of purified autoantigens may provide an insight in the mechanisms involved. Furthermore, the involvement of the 2-oxo acid dehydrogenase complexes in this autoimmune disease reveals yet another facet of these fascinating enzyme systems. 
